Vericel (VCEL) Interest Coverage Ratio (2010 - 2026)
Vericel's (VCEL) quarterly Interest Coverage Ratio came in at 50.4 in Q1 2026, up 39.72% year-on-year from 36.07 in Q1 2025, and down 136.43% quarter-over-quarter from 138.36 in Q4 2025.
Vericel (VCEL) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Vericel has disclosed Interest Coverage Ratio across 17 years of filings, most recently posting 50.4 for Q1 2026.
- Interest Coverage Ratio for Q1 2026 came in at 50.4, up 39.72% year-over-year; the trailing twelve-month figure through Mar 2026 was 24.76 (up 641.21% YoY), and the FY2025 annual result was 17.53, up 138.18% from the prior year.
- Interest Coverage Ratio came in at 50.4 for Q1 2026 at Vericel, down from 138.36 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 138.36 in Q4 2025 to a low of 454.1 in Q2 2022.
- The 5-year median for Interest Coverage Ratio is 35.71 (2024), against an average of 53.05.
- Peak annual rise in Interest Coverage Ratio reached 236.42% in 2025, while the deepest fall reached 134.11% in 2025.
- Vericel's Interest Coverage Ratio stood at 27.29 in 2022, then surged by 199.08% to 81.61 in 2023, then soared by 47.03% to 119.99 in 2024, then grew by 15.31% to 138.36 in 2025, then tumbled by 136.43% to 50.4 in 2026.
- The last three Interest Coverage Ratio figures came in at 50.4 (Q1 2026), 138.36 (Q4 2025), and 21.84 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | -50.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.40 |
| Dec 31, 2025 | 138.36 |
| Sep 30, 2025 | 21.84 |
| Jun 30, 2025 | -12.92 |
| Mar 31, 2025 | -83.61 |
| Dec 31, 2024 | 119.99 |
| Sep 30, 2024 | -16.01 |
| Jun 30, 2024 | -39.42 |
| Mar 31, 2024 | -35.71 |
| Dec 31, 2023 | 81.61 |
| Sep 30, 2023 | -33.71 |
| Jun 30, 2023 | -40.01 |
| Mar 31, 2023 | -56.39 |
| Dec 31, 2022 | 27.29 |
| Sep 30, 2022 | -64.65 |
| Jun 30, 2022 | -454.10 |
| Mar 31, 2022 | -404.06 |
| Dec 31, 2021 | 4,141.00 |
| Sep 30, 2021 | -4,961.00 |
| Jun 30, 2021 | -3,729.00 |